Neurocrine Biosciences (NBIX) Stock Analysis & Winston Score

Neurocrine Biosciences is a biotechnology company that discovers and sells medicines for neurological and psychiatric disorders. Its main product is Ingrezza (valbenazine), a pill that treats involuntary movement disorders like tardive dyskinesia and Huntington's disease chorea. The company sells primarily to patients in the United States through prescriptions written by neurologists and psychiatrists. Neurocrine makes money by selling its branded drugs directly to specialty pharmacies and distributors, which is why its gross margin is exceptionally high — nearly all revenue turns into gross profit. The company operates mainly in the US and generates roughly $2 billion in annual revenue, with Ingrezza accounting for the vast majority of sales. Its moat comes from patent protection on Ingrezza and its established relationships with specialist physicians, but heavy reliance on a single drug is a real risk — any generic competition or patent challenge could significantly hurt revenue. The company is working to diversify its pipeline through partnerships and internal drug development.